Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US House Speaker Pelosi Prioritizes Ending FDA Shutdown, Lowering Health Costs

Executive Summary

Newly-elected Speaker of the House Nancy Pelosi, D-Calif., says her priorities are ending the government shutdown, lowering health-care costs, and adoption of new House rules that could make repealing measures like the medical device tax more difficult.

You may also be interested in...



Texas Court Ruling Invalidating ACA Threatens Preexisting Illness Coverage, But It's Not The Final Word, Congress Says

A Texas federal district court judge ruled late on Dec. 14 that all of the Affordable Care Act – including parts mandating coverage of preexisting conditions, the medical device excise tax and reporting by medtech firms of payments made to health-care providers under sunshine provisions – are invalid because the health-care law's individual mandate was struck down by a 2017 tax law. But Congress and legal experts say the ruling will be challenged.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.

HHS Secretary Nominee Becerra Commits To Telehealth Expansion, Procedure Price Transparency

At two recent confirmation hearings, HHS secretary nominee Xavier Becerra promised Senators he would help expand telehealth and procedure price transparency.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel